Roivant Sciences Ltd. (ROIV)
| Market Cap | 10.43B |
| Revenue (ttm) | 23.23M |
| Net Income (ttm) | -490.63M |
| Shares Out | 682.88M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,930,137 |
| Open | 15.87 |
| Previous Close | 14.18 |
| Day's Range | 15.22 - 16.05 |
| 52-Week Range | 8.73 - 16.05 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+11.26%) |
| Earnings Date | Nov 11, 2025 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 11.26% from the latest price.
News
Roivant Sciences Ltd. - Special Call
Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participan...
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
Roivant Sciences Ltd ROIV and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial
Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical t...
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR...
Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in Bi...
Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 5:35 PM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participa...
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeti...
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-of-Concept Study Remission Data Transcript Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms...
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared a...
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and Genevan...
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Matthew Gline - CEO & Director Stephanie Lee Griffin - Vice President of Special Projects Con...
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a busi...
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Aug...
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1...
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, an...
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, Ma...
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's Fc...
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid ...
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger ...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a ...